CN1095382A - 新的菁族a环甾族化合物 - Google Patents

新的菁族a环甾族化合物 Download PDF

Info

Publication number
CN1095382A
CN1095382A CN93109540A CN93109540A CN1095382A CN 1095382 A CN1095382 A CN 1095382A CN 93109540 A CN93109540 A CN 93109540A CN 93109540 A CN93109540 A CN 93109540A CN 1095382 A CN1095382 A CN 1095382A
Authority
CN
China
Prior art keywords
compound
female
triolefin
formula
carbonyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN93109540A
Other languages
English (en)
Chinese (zh)
Inventor
D·A·霍尔特
M·A·利维
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of CN1095382A publication Critical patent/CN1095382A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0094—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
    • C07J3/005—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom the carbon atom being part of a carboxylic function
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
    • C07J7/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa
    • C07J7/002—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/0065—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by an OH group free esterified or etherified
    • C07J7/007—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by an OH group free esterified or etherified not substituted in position 17 alfa
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN93109540A 1992-06-30 1993-06-30 新的菁族a环甾族化合物 Pending CN1095382A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB929213835A GB9213835D0 (en) 1992-06-30 1992-06-30 Compounds
GB9213835.3 1992-06-30

Publications (1)

Publication Number Publication Date
CN1095382A true CN1095382A (zh) 1994-11-23

Family

ID=10717920

Family Applications (1)

Application Number Title Priority Date Filing Date
CN93109540A Pending CN1095382A (zh) 1992-06-30 1993-06-30 新的菁族a环甾族化合物

Country Status (23)

Country Link
EP (1) EP0651643A4 (es)
JP (1) JPH08500821A (es)
KR (1) KR950702118A (es)
CN (1) CN1095382A (es)
AP (1) AP412A (es)
AU (1) AU4545993A (es)
BG (1) BG99313A (es)
BR (1) BR9306748A (es)
CA (1) CA2138956A1 (es)
CZ (1) CZ334694A3 (es)
FI (1) FI946189A0 (es)
GB (1) GB9213835D0 (es)
HU (1) HUT69409A (es)
IL (1) IL106158A0 (es)
MA (1) MA22927A1 (es)
MX (1) MX9303970A (es)
NO (1) NO945074L (es)
OA (1) OA10122A (es)
RU (1) RU94046378A (es)
SI (1) SI9300350A (es)
SK (1) SK159994A3 (es)
WO (1) WO1994000125A1 (es)
ZA (1) ZA934645B (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114805462A (zh) * 2018-02-11 2022-07-29 江苏豪森药业集团有限公司 一种甾族类衍生物调节剂及其制备方法和应用

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5925774A (en) * 1991-01-07 1999-07-20 Pherin Corporation Estrenes for inducing hypothalamic effects
AU676478B2 (en) * 1992-05-20 1997-03-13 Merck & Co., Inc. New delta-17 and delta-20 olefinic and saturated 17beta- substituted-4-aza-5alpha-androstan-3-ones as 5alpha- reductase inhibitors
US5543417A (en) * 1994-10-21 1996-08-06 Merck & Co., Inc. Combination method of treating acne using 4-AZA-5α-cholestan-ones and 4-AZA-5α-androstan-ones as selective 5α-reductase inhibitors with anti-bacterial, keratolytic, or anti-inflammatory agents
GB201102913D0 (en) 2011-02-18 2011-04-06 Univ Birmingham Novel therapeutic
JP2015129095A (ja) 2013-12-19 2015-07-16 ロレアル 組成物

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4954446A (en) * 1988-05-25 1990-09-04 Smithkline Beecham Corporation Aromatic steroid 5-α-reductase inhibitors

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114805462A (zh) * 2018-02-11 2022-07-29 江苏豪森药业集团有限公司 一种甾族类衍生物调节剂及其制备方法和应用
CN114805462B (zh) * 2018-02-11 2024-06-18 江苏豪森药业集团有限公司 一种甾族类衍生物调节剂及其制备方法和应用

Also Published As

Publication number Publication date
MA22927A1 (fr) 1994-04-01
HUT69409A (en) 1995-09-28
CA2138956A1 (en) 1994-01-06
FI946189A (fi) 1994-12-30
EP0651643A4 (en) 1995-10-04
RU94046378A (ru) 1996-10-10
JPH08500821A (ja) 1996-01-30
SK159994A3 (en) 1996-01-10
AU4545993A (en) 1994-01-24
BR9306748A (pt) 1998-12-08
MX9303970A (es) 1994-04-29
BG99313A (en) 1995-09-29
AP412A (en) 1995-09-29
EP0651643A1 (en) 1995-05-10
WO1994000125A1 (en) 1994-01-06
IL106158A0 (en) 1993-10-20
NO945074L (no) 1995-02-16
SI9300350A (sl) 1993-12-31
ZA934645B (en) 1994-01-25
CZ334694A3 (en) 1995-10-18
KR950702118A (ko) 1995-06-19
AP9300542A0 (en) 1993-07-31
GB9213835D0 (en) 1992-08-12
FI946189A0 (fi) 1994-12-30
OA10122A (en) 1996-12-18
NO945074D0 (no) 1994-12-29

Similar Documents

Publication Publication Date Title
CN1041054C (zh) 含有甾类5－α－还原酶抑制剂的药物组合物制备方法
CN1051181A (zh) 芳族甾类5-α-还原酶抑制剂制备方法
CN1031942C (zh) 新的药用甾体的制备方法
CN1061052C (zh) 11β－芳基－4－雌烯及其药物上适宜的酸加成盐的制药应用
CN1085223A (zh) 17-β-取代的-4-氮杂-5α-雄烷-3-酮衍生物
CN1234738A (zh) 奥氮平二水合物d
CN1322130A (zh) 抑制3型3α－羟基类固醇脱氢酶
CN1906180A (zh) 新的长效β－2－激动剂及其作为药物的用途
CN1294577A (zh) 钾通道抑制剂
CN1085224A (zh) 氟化17β-取代的4-氮杂-5α-雄甾烷-3-酮衍生物
CN1129441A (zh) 维生素d类似物
CN1036392C (zh) 环取代的2-氨基四氢萘和3-氨基苯并二氢吡喃的制法
CN1054856C (zh) 取代的19-去甲甾类及其制备方法和药物组合物
CN1081682A (zh) 甾类衍生物
CN1067057A (zh) 不饱和的17β-取代的3-羧基甾族化合物的制备方法
CN1105362A (zh) 降低血清胆固醇的方法
CN1993375A (zh) 具有雄激素作用的甾类前药
CN1134155A (zh) 雄甾烯酮
CN1095382A (zh) 新的菁族a环甾族化合物
CN1101916A (zh) 17α和17β取代的酰基-3-羧基3，5-二烯甾族化合物
CN1030921C (zh) 制备δ4-甾类化合物的方法
CN1501930A (zh) 新的含有吡啶和环己烯基的吡咯并苯并二氮杂�羧酰胺和其衍生物;保胎催产素受体拮抗剂
CN1326461A (zh) 减数***调控化合物
CN1751059A (zh) 具有抗肿瘤活性的2－取代的雌－1,3,5(10)－三烯－3－基氨基磺酸酯
CN1102529A (zh) 氟化4-氨基雄甾二烯酮衍生物及其制备方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C01 Deemed withdrawal of patent application (patent law 1993)
WD01 Invention patent application deemed withdrawn after publication